OCGN Ocugen
Price Chart
Executive Summary
Ocugen reported Q1 2026 EPS of -$0.06, a 16.1% miss vs consensus of -$0.05, with revenue of $1.53M (in line). The miss was offset by positive clinical data (OCU410 Phase 2 GA trial showing 31% lesion reduction) and a $115M convertible note offering that extends cash runway into 2028, but the EPS miss and widening operating loss (-$17.8M vs -$14.5M YoY) are near-term headwinds.
Actionable Insight
The EPS miss and widening loss are bearish, but the $115M convertible offering and positive OCU410 Phase 2 data provide a floor. Watch for Phase 3 trial initiations (OCU410 in H2 2026) and BLA submission timelines (OCU400 by Q2 2027). The stock may trade on clinical catalysts rather than near-term financials.
Key Facts
- Q1 2026 EPS -$0.06 vs consensus -$0.05 (16.1% miss)
- Q1 2026 revenue $1.53M vs consensus $358K (beat, but revenue is immaterial at ~$626M market cap)
- Operating loss widened to -$17.8M from -$14.5M YoY
- Cash, equivalents, and restricted cash $32.2M as of March 31, 2026
- Closed $115M convertible note offering (6.75%, due 2034) expected to extend cash runway into 2028
- Positive 12-month OCU410 Phase 2 data: 31% lesion reduction (p<0.05) in GA; 20% of patients showed no progression
- Phase 3 liMeliGhT trial for RP fully enrolled (N=140); topline data expected Q1 2027
- BLA submissions planned: OCU400 by Q2 2027, OCU410ST by mid-2027, OCU410 by 2028
- 338.3M shares outstanding as of March 31, 2026
Financial Impact
EPS miss of 16.1% vs consensus; operating loss increased $3.3M YoY; $115M convertible offering provides runway into 2028 but adds ~$7.8M annual interest expense
Risk Factors
- EPS miss and widening operating loss signal deteriorating near-term profitability
- Convertible note adds $7.8M annual interest expense and potential dilution if converted
- Clinical trial failures or regulatory delays could impair pipeline value
- High cash burn rate ($19.4M operating expenses in Q1) may require further financing
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287702 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
8-K
| $1.22 awaiting T+20 | awaiting T+20 | — | $1.21 (−0.82%) |
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $1.24 awaiting T+20 | awaiting T+20 | — | $1.21 (−2.02%) |
|
May 5, 2026
5w ago
|
8-K
| $1.49 $1.34 | ▼ −10.07% | ▼ −15.02% | $1.21 (−18.79%) |
|
May 5, 2026
5w ago
|
Press Release
| $1.49 $1.34 | ▼ −10.07% | ▼ −15.02% | $1.21 (−18.79%) |
|
May 5, 2026
5w ago
|
Press Release
| $1.49 $1.34 | ▲ +10.07% | ▲ +15.02% | $1.21 (+18.79%) |
|
May 4, 2026
5w ago
|
8-K
| $1.49 $1.34 | ▼ −10.07% | ▼ −15.02% | $1.21 (−18.79%) |
|
Apr 29, 2026
6w ago
|
Press Release
| $1.68 $1.38 | ▼ −17.86% | ▼ −23.32% | $1.21 (−27.98%) |
|
Mar 24, 2026
11w ago
|
Press Release
| $1.92 $1.68 | ▼ −12.50% | ▼ −21.40% | $1.21 (−36.98%) |
|
Mar 4, 2026
14w ago
|
8-K
| $1.96 $1.79 | ▼ −8.67% | ▼ −4.26% | $1.21 (−38.27%) |
|
Mar 4, 2026
14w ago
|
8-K
| $1.96 $1.79 | ▼ −8.67% | ▼ −4.26% | $1.21 (−38.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access